News
Kindred Bio Expands of Manufacturing Agreement with Vaxart for COVID-19 Vaccine
Kindred Biosciences, Inc., a biopharmaceutical company developing novel biologics, announced it has expanded an agreement with Vaxart, Inc. for the manufacture of Vaxartโs oral...
News
Astellas and Seagen Announce Positive Topline Results from Second Cohort of Patients in Phase 2 Trial
Astellas Pharma Inc. and Seagen Inc. announced positive topline results from the second cohort of patients in the pivotal phase 2 single-arm clinical trial...
News
Merck Licenses CRISPR Genome-Editing Technology to PanCELLa and Takara Bio USA
Merck, a leading science and technology company,ย announced that it has signed agreements licensing its CRISPR technology to two companies โ PanCELLa, a cell...
Press Releases
Merck’s New VirusExpress Platform Speeds Development of Cell and Gene Therapies
Merck, a leading science and technology company, has bolstered its viral vector manufacturing capabilities with the launch of its VirusExpressโข Lentiviral Production Platform. This...
Packaging & Labelling
Dnata becomes first to offer fully integrated, temperature-controlled cool chain for pharma cargo in Singapore
dnata, one of the worldโs leading air services providers, has further enhanced its pharma handling capabilities in Singapore by launching cool dollies in its...
News
Direct Biologics Granted Expanded Access by FDA for ExoFlo in the Treatment of COVID-19
Direct Biologics, LLC, announced that the FDA has granted expanded access for ExoFlo in the treatment of patients with COVID-19 associated acute respiratory distress...
Clinical Trials
Astrazeneca Says Covid-19 Long-Acting Antibody Combination AZD7442 Rapidly Advances Into Phase III Clinical Trials
AstraZenecaโs long-acting antibody (LAAB) combination, AZD7442, will advance into two Phase III clinical trials in more than 6,000 participants at sites in and outside...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read
















